Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs

Bibliography

• Perou CM, Sorlie T, Eisen MB, Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361(10):958-67
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
   PubMed Web of Science ®Google Scholar
• Keedy VL, Temin S, Somerfield MR, American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29(15):2121-7
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011;364(8):772-4
   PubMed Web of Science ®Google Scholar
• Group GSTM-A. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28(7):1247-53
   Google Scholar
• Kim TW, Lee H, Kang Y-K, Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004;10(9):3076-81
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008;54(11):1770-9
   PubMed Web of Science ®Google Scholar
• Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010;9(5):363-6
   PubMed Web of Science ®Google Scholar
• Reid A, Baird R, Workman P. Emerging molecular technologies: drugs interfering with signal transduction pathways. Chapter 17. Principles of Molecular oncology. 3rd edition. Springer; 2008
   Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001. 69(3):89-95
   Google Scholar
• Park JW, Kerbel RS, Kelloff GJ, Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004;10(11):3885-96
   PubMed Web of Science ®Google Scholar
• NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991;265:391-5
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R, American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-312
   PubMed Web of Science ®Google Scholar
• Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007;96:213-68
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990;8(10):1739-53
   Google Scholar
• Thun MJ, DeLancey JO, Center MM, The global burden of cancer: priorities for prevention. Carcinogenesis 2010;31(1):100-10
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106-30
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90
   PubMed Web of Science ®Google Scholar
• Lu C, Onn A, Vaporciyan AA, "78: Cancer of the Lung". Holland-Frei Cancer Medicine. 8th edition. People's Medical Publishing House; 2010; ISBN: 9781607950141
   Google Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Crowley J, Chansky K, The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2(8):706-14
   PubMed Web of Science ®Google Scholar
• Aplan PD. Causes of oncogenic chromosomal translocation. Trends Genet 2006;22(1):46-55
   Google Scholar
• Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007;7(4):233-45
   PubMed Web of Science ®Google Scholar
• Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol Med 2006;12(11):529-36
   Google Scholar
• Tomlins SA, Rhodes DR, Perner S, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-8
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6
   PubMed Web of Science ®Google Scholar
• Pollmann M, Parwaresch R, Adam-Klages S, Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp Cell Res 2006;312(17):3241-51
   PubMed Web of Science ®Google Scholar
• Eichenmuller B, Everley P, Palange J, The human EMAP-like protein-70 (ELP70) is a microtubule destabilizer that localizes to the mitotic apparatus. J Biol Chem 2002(2):1301-9
   Google Scholar
• Smith TF, Gaitatzes C, Saxena K, Neer EJ. The WD repeat: a common architecture for diverse functions. Trends Biochem Sci 1999;24(5):181-5
   PubMed Web of Science ®Google Scholar
• Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 2002;20(17):3691-702
   PubMed Web of Science ®Google Scholar
• George RE, Sanda T, Hanna M, Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455(7215):975-8
   PubMed Web of Science ®Google Scholar
• Pulford K, Lamant L, Espinos E, The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004;61(23):2939-53
   PubMed Web of Science ®Google Scholar
• Debelenko LV, Raimondi SC, Daw N, Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 2011;24(3):430-42
   Google Scholar
• Inamura K, Takeuchi K, Togashi Y, EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3(1):13-17
   PubMed Web of Science ®Google Scholar
• Kuo Y-W, Wu S-G, Ho C-C, Shih J-Y. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010;5(12):2039-40
   PubMedGoogle Scholar
• McDermott U, Iafrate AJ, Gray NS, Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68(9):3389-95
   PubMed Web of Science ®Google Scholar
• Koh Y, Kim DW, Kim TM, Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma. suggestion for an effective screening strategy for these tumors. J Thorac Oncol 2011;6(5):905-12
   Google Scholar
• Wong DW, Leung EL, So KK, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115(8):1723-33
   PubMed Web of Science ®Google Scholar
• Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46(10):1773-80
   PubMed Web of Science ®Google Scholar
• Wong DW, Leung EL, Wong SK, A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011;117(12):2709-18
   PubMed Web of Science ®Google Scholar
• Togashi Y, Soda M, Sakata S, KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS ONE 2012;7(2):e31323
   Google Scholar
• Soda M, Takada S, Takeuchi K, A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105(50):19893-7
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14(13):4275-83
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27(26):4247-53
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6(12 Pt 1):3314-22
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703
   PubMed Web of Science ®Google Scholar
• Crino L, Kim D, Riely GJ, Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29(Suppl):abstract 7514
   Google Scholar
• Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI® (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer. 2012. Available from: http://www.pfizer.com/news/press_releases/pfizer_press_release.j
   Google Scholar
• Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov 2011;10:897-8
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou SH, ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30(8):863-70
   PubMed Web of Science ®Google Scholar
• FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. 2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856html
   Google Scholar
• Vysis ALK Break Apart FISH Probe Kit; Vysis Paraffin Pretreatment IV and Post Hybridization Wash Buffer Kit; ProbeChek ALK Negative Control Slides; and ProbeChek ALK Positive Control Slides - P110012. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p110012
   Google Scholar
• Brewer GJ. Drug development for orphan diseases in the context of personalized medicine. Transl Res 2009;154(6):314-22
   Google Scholar
• Ferlay J, Shin HR, Bray F, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
   PubMed Web of Science ®Google Scholar
• Sullivan R, Peppercorn J, Sikora K, Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12(10):933-80
   PubMed Web of Science ®Google Scholar
• Shulman SR, Manocchia M. The US orphan drug programme 1983 – 1995. Pharmacoeconomics 1997;12(3):312-26
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25(2):209-16
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. Available from: http:/www.cancer.org/Cancer/CancerBasics/lifetime- probability-of-developing-or-dying-from-cancer 2010
   Google Scholar
• Barker AD, Sigman CC, Kelloff GJ, I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86(1):97-100
   PubMed Web of Science ®Google Scholar
• Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012;366(26):2438-41
   PubMed Web of Science ®Google Scholar
• Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30(15):1747-9
   PubMedGoogle Scholar
• Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 2010;95(2-3):216-28
   PubMed Web of Science ®Google Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101(15):1044-8
   PubMedGoogle Scholar
• US Food and Drug Administration. Mylotarg (gemtuzumab ozogamicin): market withdrawal. 2010. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlerts forHumanMedicalProducts/ucm216458.htm [Accessed 21 April 2011]
   Google Scholar
• Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 2011;305(22):2320-6
   PubMed Web of Science ®Google Scholar
• Richey EA, Lyons EA, Nebeker JR, Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 2009;27(26):4398-405
   PubMed Web of Science ®Google Scholar
• Johnson JR, Ning YM, Farrell A, Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst 2011;103(8):636-44
   PubMedGoogle Scholar
• Parker JS, Mullins M, Cheang MCU, Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27(8):1160-7
   PubMed Web of Science ®Google Scholar